ESR1 and breast cancer: Selective estrogen receptor modulators (SERMs) have also been tried as a treatment for postmenopausal osteoporosis because they have a lower breast cancer risk than that seen with estrogen itself, but the SERMs still carry the risk of developing thromboembolic episodes [35, 36].